학술논문
Time-to-response for patients with relapsed/refractory diffuse large B cell and high grade B cell lymphoma treated with polatuzumab-based therapy.
Document Type
Letter
Author
Source
Subject
*B cell lymphoma
*DIFFUSE large B-cell lymphomas
*B cells
*
*
Language
ISSN
1042-8194
Abstract
In this series of 50 patients with relapsed/refractory DLBCL/HGBL treated with PV-based therapies, we report a median time-to first clinical, radiographic or first response as 21.5, 64 and 22 days, with responses durations estimated to be 180 days or greater in over half of patients evaluable for response. Excluding the 6 responding patients discontinuing PV-based therapy due to proceeding with cellular therapy, 12 patients with clinical response and 13 patients with radiographic response were evaluable for duration of response. Polatuzumab vedotin (PV), an anti-CD79b antibody drug conjugate, was approved by the United States (US) Food and Drug Administration in June 2019 for relapsed/refractory diffuse large B cell lymphoma (DLBCL) patients having received >=2 lines of prior therapy in combination with rituximab and bendamustine based upon results from a randomized phase 2 clinical trial [[1]]. [Extracted from the article]